Literature DB >> 32279469

Off-label prescribing in the midst of a pandemic: The case of hydroxychloroquine.

J Simon Bell, John A Bell, Darren J Creek.   

Abstract

There is currently no robust evidence to support prescribing hydroxychloroquine as a treatment or prophylaxis for COVID-19.

Entities:  

Year:  2020        PMID： 32279469     DOI： 10.31128/AJGP-COVID-06

Source DB:  PubMed          Journal:  Aust J Gen Pract


  5 in total

Review 1.  Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.

Authors:  Virgilio Galvis; Francesca Romana Spinelli; Alejandro Tello; Claudia L Sossa; Juan D Higuera; Edgar D Gómez; Sergio E Serrano; Paul A Camacho; Federico G Velez
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2020-05-31       Impact factor: 4.872

Review 2.  Hydroxychloroquine as Prophylaxis for Coronavirus SARS-CoV-2 Infection: Review of the Ongoing Clinical Trials.

Authors:  Virgilio Galvis; Francesca Romana Spinelli; Alejandro Tello; Claudia L Sossa; Juan D Higuera; Edgar D Gómez; Sergio E Serrano; Paul A Camacho; Federico G Velez
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2020-09-14

3.  Household Drug Stockpiling and Panic Buying of Drugs During the COVID-19 Pandemic: A Study From Jordan.

Authors:  Sura Al Zoubi; Lobna Gharaibeh; Hatim M Jaber; Zaha Al-Zoubi
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.988

4.  Pharmacists' experiences of consumer stockpiling: insights from COVID-19.

Authors:  Eliza E Cameron; Simon A Moss; Samuel J Keitaanpaa; Mary-Jessimine A Bushell
Journal:  J Pharm Pract Res       Date:  2021-12-05

5.  Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.

Authors:  Lotfollah Davoodi; Seyed Mohammad Abedi; Ebrahim Salehifar; Reza Alizadeh-Navaei; Hamed Rouhanizadeh; Ghasemali Khorasani; Seyed Jalal Hosseinimehr
Journal:  Int J Clin Pract       Date:  2020-07-17       Impact factor: 3.149
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.